Second quarter 2008 results date notification - 31 July 2008
Basingstoke, UK and Philadelphia, US – July 4, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on Thursday 31 July 2008
| Results press release will be issued at: | 12:00 BST / 07:00 EDT |
| Investor meeting and conference call time: | 14:30 BST / 09:30 EDT |
Investor & Analyst meeting and conference call:
Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT.
The meeting will take place at Holborn Bars, 138-142 Holborn, London EC1 2NQ.
Please email claire.rowell@fd.com to register to attend this meeting in London.
The details of the conference call are as follows:
| UK and International dial in | 44 (0) 203 023 4496 |
| US dial in: | 1 866 966 5335 |
| Password/Conf ID: | Shire |
Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
| UK and International dial in | 44 (0) 208 196 1998 |
| US dial in | 1 866 583 1035 |
| Pin code | 3008632 |
| Webcast replay: | www.shire.com, in the investors section |
For further information please contact:
| Investor Relations | Souheil Salah (Rest of the World) | +44 1256 894 160 |
| | Emily Berish (North America) | +1 484 595 8546 |
Notes to editors
SHIRE LIMITED
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
